ストックスクリーナーアプリを入手
1.7295
3.92%
-0.0705
前日終値:
$1.80
開ける：
$1.8
24時間の取引高:
7,053
Relative Volume:
0.19
時価総額：
$39.43M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.84%
1か月 パフォーマンス:
+1.74%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.7295
$1.803
1週間の範囲:
$1.529
$1.82
52週間の値動き範囲:
$1.35
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
RNTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.7295 | 39.43M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.03 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.52 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2017-07-24 | 開始されました | BofA/Merrill | Buy |
| 2017-07-24 | 開始されました | Jefferies | Buy |
| 2017-07-24 | 開始されました | William Blair | Outperform |
Rein Therapeutics Inc (RNTX) 最新ニュース
Rein Therapeutics to integrate Qureight’s platform in trial of IPF treatment - Yahoo Finance
Rein Therapeutics and Qureight Ltd Announce Planned Integration of Deep-Learning Platform for Phase 2 Trial of LTI-03 in Patients with IPF - PR Newswire
Rein Therapeutics to Present at The Citizens Life Sciences Conference 2025 - Citizen Tribune
Rein Therapeutics Announces Abstract Accepted for Presentation at the American Thoracic Society 2025 International Conference - The Victoria Advocate
Breakthrough Lung Regeneration Study: Rein Therapeutics to Present New IPF Treatment Data at ATS 2025 - Stock Titan
Rein Therapeutics Granted Two Patents Covering the Novel Formulation and Administration Methods of Dry Powder LTI-03 for the Treatment of Respiratory Diseases - The Malaysian Reserve
Rein Therapeutics (RNTX) Secures Two Key Patents for Innovative Lung Treatment | RNTX Stock News - GuruFocus
Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases - marketscreener.com
Antibiotics Might Increase Risk of Childhood Asthma, Allergies - WFMZ.com
Muscle Quality Could Be Key To Successful Hip Replacement - WFMZ.com
Early Menopause Might Mean Greater Age-Related Brain Decline - WFMZ.com
Microplastics Could Be Contributing To Clogged Arteries - WFMZ.com
Psilocybin Use Dramatically Increasing In U.S. - WFMZ.com
Tesla Board Gets an Earful From State Treasurers Over Musk’s Focus - Yahoo Finance
Rein Therapeutics Announces a Publication in Biomedicines on the - GuruFocus
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - MarketScreener
Rein Therapeutics (RNTX) Showcases Promising Peptide for Lung Fi - GuruFocus
Cancer-fighting implant shows promise in treating tumors - WFMZ.com
ITC Makes Affirmative Preliminary Determination in Trade Cases on Chassis from Mexico, Thailand, and Vietnam, Wiley Rein LLP Reports - Yahoo Finance
Equities Analysts Offer Predictions for RNTX Q1 Earnings - Defense World
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Will the tariffs lead to a recession? Here's how to know if we're in one - WFMZ.com
Rein Therapeutics, Inc. SEC 10-K Report - TradingView
Health Secretary Says Some Cuts to CDC Will Be Reversed - WFMZ.com
RFK Jr. Touts Vaccine While At Funeral of Texas Girl Who Died of Measles - WFMZ.com
Lawmakers may test Trump on tariffs this week as fears of a GOP election 'decimation' grow - Yahoo Finance
Some Folks Hit With Fees for Using Health Care Message Portals - WFMZ.com
RNTX stock touches 52-week low at $1.6 amid market challenges - Investing.com Canada
RNTX stock touches 52-week low at $1.6 amid market challenges By Investing.com - Investing.com South Africa
Trump says things are 'going very well' after worst stock market drop in years over tariffs - WFMZ.com
Aileron Therapeutics, Inc. Announces New Appointments - MarketScreener
Rein Therapeutics Delays Annual Report Filing - TipRanks
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial - Frontiers
NCLA Asks Sixth Circuit to Rein in FINRA’s Unlawful Prosecution Regime - Yahoo Finance
Modi Banks on Households to Rein In a $346 Billion Debt Pile - Yahoo Finance
Crude oil drives higher with focus on geopolitical risks, OPEC+ plan to rein in production - Seeking Alpha
Oil prices rise for second consecutive week on expected tighter supply - Yahoo Finance
Congo Considers Asking Indonesia to Help Rein In Cobalt Supply - Yahoo Finance
USAID reinstates contracts for Georgia company that helps feed malnourished kids after Elon Musk responds to CNN reporting - AOL
Reeves Pledges to Rein In UK Borrowing as Welfare Backlash Grows - Yahoo Finance
Daybreak West March 11: Ag chair seeks to rein in CARB costs - Agri-Pulse
OpinionThrough ‘radical transparency,’ Kennedy can finally rein in Big Pharma - AOL
Trump's Plan To Rein In Regulators Could Erode Market Trust, Says $2.3 Trillion Asset Manager - Yahoo Finance
Saratoga Springs event celebrates Belmont countdown while supporting therapeutic horses - WRGB
Carney Vows to Rein In Government Spending, Cap Public Service in Canada - Yahoo Finance
British biotech rebrands as Octavian, seeking to establish new empire after setbacks in 2024 - Fierce Pharma
Should You Invest in Wolfspeed Inc (WOLF) Now? - The News Heater
Esco Technologies, Inc (ESE) Shares Up Despite Recent Market Volatility - The News Heater
PDD Holdings Inc ADR (PDD) Shares Rise Despite Market Challenges - The News Heater
Palantir Technologies Inc (PLTR) Stock: A Closer Look at the Analyst Ratings - The News Heater
Rein Therapeutics (RNTX) Income Statement & Balance Sheet 2025 - MarketBeat
Rein Therapeutics Inc (RNTX) 財務データ
Rein Therapeutics Inc (RNTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
5.24%
大文字化:
|
ボリューム (24 時間):